Ardian has signed an exclusive agreement to acquire a majority stake in Fermax from MCH Private Equity and Eurazeo. MCH Private Equity and Eurazeo’s disposal will deliver returns with a cash-on-cash ...

Ardian, firma de inversión privada líder mundial, anuncia un acuerdo para adquirir una participación mayoritaria en Fermax, fabricante valenciano de sistemas de intercomunicación, soluciones de ...

El fondo de capital privado Ardian ha firmado un acuerdo exclusivo para adquirir una participación mayoritaria en Fermax, el fabricante español líder en sistemas de intercomunicación, soluciones de ...

NEEDHAM, Mass., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal ...

The immunotherapy CAN-2409 added to standard EBRT without ADT is a potential paradigm-shifting therapy for localized intermediate- to high-risk prostate cancer. CAN-2409, an adenoviral vector, plus ...

Candel Therapeutics CADL announced that the FDA has granted the Regenerative Medicine Advanced Therapy (RMAT) designation to its investigational adenovirus immunotherapy candidate, CAN-2409 ...

NEEDHAM, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal ...

Candel Therapeutics essentially uses a dual-virus strategy with CAN-2409 (adenovirus HSV-tk) and CAN-3110 (HSV oncolytic) immunotherapies. First, CAN-2409 reported promising Phase 3 results for ...

In December, the share price of Candel Therapeutics surged by more than 200% when the company revealed the success of a phase 3 trial of its multimodal biological immunotherapy CAN-2409 (aglatimagene ...

Hands-free VEO-XS monitor. Characterised by its small size and extra-flat thickness. Thanks to its OSD menu and the layout of the buttons, interaction with the user is simple and intuitive. Made of ...